Feb. 7, 2007 — Velcura Therapeutics, Inc. will be recognized as one of the "Michigan 50 Companies to Watch," an award designed to shine the spotlight on second-stage companies that is sponsored by the Edward Lowe Foundation. The award will be presented April 12, 2007 at the Kellogg Hotel and Conference Center in Lansing, MI.

Aug. 30, 2006 — Velcura Therapeutics, Inc. has received a Phase I Small Business Innovation Research (SBIR) grant for $274,000 from the National Institute on Aging (NIA) to further identify the genes and or protein networks modulated during human bone formation. SBIR is a competitively awarded, three-phase Federal Government program designed to stimulate technological innovation and provide opportunities for small business.

June 15, 2006 — As it prepares to move into clinical trials on a new drug for osteoporosis, Velcura Therapeutics, Inc. has chosen to work with Hurley Consulting Associates, Ltd, which will assist the biotech company with the development program design, FDA submissions and clinical trial data collection and analysis. Hurley Consulting already has successfully worked with sponsors in designing development programs and prepared osteoporosis new drug applications (NDAs) for submission in the U.S. and Europe.

Aug. 9, 2005 — U.S. biotechnology company Velcura Therapeutics®, Inc. announced a license agreement with Nippon Chemiphar Co. (Chemiphar), Ltd., a Japanese pharmaceutical company listed on the Tokyo Stock Exchange. The license agreement enables the two companies to further develop new small-molecule therapies for osteoporosis and other bone diseases. This is a critical unmet need, as osteoporosis is second only to cardiovascular disease as a world health problem, according to the World Health Organization.

July 12, 2005 — ANN ARBOR, MICH., July 12, 2005 – The National Institute on Aging, National Institutes of Health (NIH) awarded Velcura Therapeutics®, Inc. a $1.3 million Phase II Small Business Innovation Research (SBIR) grant entitled "Proteomics-based drug discovery in human osteoblasts".